- Report
- October 2024
- 189 Pages
Global
From €3235EUR$3,545USD£2,759GBP
€3595EUR$3,939USD£3,065GBP
- Report
- April 2025
- 194 Pages
Global
From €5339EUR$5,850USD£4,552GBP
- Report
- August 2024
- 140 Pages
Global
From €2737EUR$2,999USD£2,334GBP
- Report
- May 2024
- 184 Pages
Global
From €2282EUR$2,500USD£1,945GBP
- Report
- May 2024
- 187 Pages
Global
From €4107EUR$4,500USD£3,502GBP
- Report
- April 2025
- 78 Pages
Global
From €5339EUR$5,850USD£4,552GBP
- Report
- December 2023
- 171 Pages
Global
From €4061EUR$4,450USD£3,463GBP
- Report
- April 2023
- 147 Pages
Global
From €4517EUR$4,949USD£3,851GBP
- Report
- February 2024
- 110 Pages
Global
From €4335EUR$4,750USD£3,696GBP
- Report
- July 2024
- 101 Pages
Global
From €3500EUR$4,108USD£3,089GBP
- Report
- May 2023
- 100 Pages
Global
From €3500EUR$4,108USD£3,089GBP
- Report
- May 2022
- 42 Pages
Global
From €1825EUR$2,000USD£1,556GBP
The Hospital Acquired Infection Drug market is a subset of the Infectious Diseases Drugs market. It focuses on drugs used to treat infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). These drugs are typically antibiotics, antivirals, antifungals, and antiparasitics. They are used to treat infections that are resistant to traditional treatments, or to prevent infections in patients with weakened immune systems.
The Hospital Acquired Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bayer. Show Less Read more
